Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene

Vaccine

Volumn 26, Issue 50, 2008, Pages 6405-6414

  Cenna, Jonathan ^a   Tan, Gene S ^a   Papaneri, Amy B ^a   Dietzschold, Bernhard ^a,b   Schnell, Matthias J ^a,b   McGettigan, James P ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Antibody subclass; Isotypes; Phosphoprotein; Post exposure prophylaxis; Rabies virus; Replication deficient; Vaccine; Viral vector

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INACTIVATED VACCINE; LIVE VACCINE; PHOSPHOPROTEIN; RABIES VACCINE; RAG2 PROTEIN; RIBONUCLEOPROTEIN; VIRUS ANTIGEN; VIRUS GLYCOPROTEIN; VIRUS RNA; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG EFFICACY; EXPRESSION VECTOR; FEMALE; GENE DELETION; GENE EXPRESSION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABIES; RABIES VIRUS; SPINAL CORD; SURVIVAL RATE; ULTRAVIOLET IRRADIATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; CRICETINAE; FEMALE; GENE DELETION; GENE DOSAGE; GENETIC VECTORS; MICE; MICE, INBRED BALB C; PHOSPHOPROTEINS; RABIES; RABIES VACCINES; RABIES VIRUS; VIRAL ENVELOPE PROTEINS; VIRUS DISEASES;

EID: 55749084702     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.08.069     Document Type: Article

References (54)

1. Knobel D.L., Cleaveland S., Coleman P.G., Fevre E.M., Meltzer M.I., Miranda M.E., et al. Re-evaluating the burden of rabies in Africa and Asia. Bulletin of the World Health Organization 83 5 (2005) 360-368
2. McGettigan J.P., Pomerantz R.J., Siler C.A., McKenna P.M., Foley H.D., Dietzschold B., et al. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. Journal of Virology 77 1 (2003) 237-244
3. McKenna P.M., Koser M.L., Carlson K.R., Montefiori D.C., Letvin N.L., Papaneri A.B., et al. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. Journal of Infectious Diseases 195 7 (2007) 980-988
4. Pirofski L.A., and Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clinical Microbiology Reviews 11 1 (1998) 1-26
5. Conzelmann K.K., Cox J.H., Schneider L.G., and Thiel H.J. Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19. Virology 175 2 (1990) 485-499
6. Dietzschold B., Rupprecht C.E., Fu Z.F., and Koprowski H. Rhabdoviruses. In: Fields B.N. (Ed). Fields virology (1996), Lippincott-Raven Publishers, Philadelphia, PA 1137-1152
7. Rose J.K., and Schubert M. Rhabdovirus genomes and their products (1987), Plenum Publishing Corp., New York
8. Brzozka K., Finke S., and Conzelmann K.K. Identification of the rabies virus alpha/beta interferon antagonist: phosphoprotein P interferes with phosphorylation of interferon regulatory factor 3. Journal of Virology 79 12 (2005) 7673-7681
9. Shoji Y., Inoue S., Nakamichi K., Kurane I., Sakai T., and Morimoto K. Generation and characterization of P gene-deficient rabies virus. Virology 318 1 (2004) 295-305
10. Morimoto K., Shoji Y., and Inoue K. Characterization of P gene-deficient rabies virus: propagation, pathogenicity and antigenicity. Virus Research 111 (2005) 61-67
11. Lafon M., Lafage M., Martinez-Arends A., Ramirez R., Vuillier F., Charron D., et al. Evidence for a viral superantigen in humans. Nature 358 6386 (1992) 507-510 [see comments]
12. Lodmell D.L., Smith J.S., Esposito J.J., and Ewalt L.C. Cross-protection of mice against a global spectrum of rabies virus variants. Journal of Virology 69 8 (1995) 4957-4962
13. Lodmell D.L., and Ewalt L.C. Rabies vaccination: comparison of neutralizing antibody responses after priming and boosting with different combinations of DNA, inactivated virus, or recombinant vaccinia virus vaccines. Vaccine 18 22 (2000) 2394-2398
14. Li W.H., Zhang Y., Wang S.H., Liu L., and Yang F. Recombinant replication-defective adenovirus based rabies vaccine. Chung Kuo i Hsueh Ko Hsueh Yuan Hsueh Pao Acta Academiae Medicinae Sinicae 25 6 (2003) 650-654
15. Lees C.Y., Briggs D.J., Wu X., Davis R.D., Moore S.M., Gordon C., et al. Induction of protective immunity by topic application of a recombinant adenovirus expressing rabies virus glycoprotein. Veterinary Microbiology 85 4 (2002) 295-303
16. Li W., Zhang Y., and Wang S. Immune response of mice to replication-defective recombinant adenovirus containing glycoprotein gene of rabies virus 3aG strain. Chinese Journal of Experimental & Clinical Virology 15 1 (2001) 61-65
17. Vos A., Neubert A., Pommerening E., Muller T., Dohner L., Neubert L., et al. Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration. Journal of General Virology 82 9 (2001) 2191-2197
18. Lodmell D.L., Ray N.B., Parnell M.J., Ewalt L.C., Hanlon C.A., Shaddock J.H., et al. DNA immunization protects nonhuman primates against rabies virus. Nature Medicine 4 8 (1998) 949-952
19. Lodmell D.L., Ray N.B., and Ewalt L.C. Gene gun particle-mediated vaccination with plasmid DNA confers protective immunity against rabies virus infection. Vaccine 16 2-3 (1998) 115-118
20. Lodmell D.L., Ray N.B., Ulrich J.T., and Ewalt L.C. DNA vaccination of mice against rabies virus: effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL). Vaccine 18 11-12 (2000) 1059-1066
21. Lodmell D.L., Parnell M.J., Bailey J.R., Ewalt L.C., and Hanlon C.A. One-time gene gun or intramuscular rabies DNA vaccination of non-human primates: comparison of neutralizing antibody responses and protection against rabies virus 1 year after vaccination. Vaccine 20 5-6 (2001) 838-844
22. Ray N.B., Ewalt L.C., and Lodmell D.L. Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection. Vaccine 15 8 (1997) 892-895
23. Fu Z.F., Wunner W.H., and Dietzschold B. Immunoprotection by rabies virus nucleoprotein. Current Topics in Microbiology & Immunology 187 (1994) 161-172
24. Fu Z.F., Dietzschold B., Schumacher C.L., Wunner W.H., Ertl H.C., and Koprowski H. Rabies virus nucleoprotein expressed in and purified from insect cells is efficacious as a vaccine. Proceedings of the National Academy of Sciences of the United States of America 88 5 (1991) 2001-2005
25. Aspden K., Passmore J.A., Tiedt F., and Williamson A.L. Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector. Journal of General Virology 84 8 (1985) 1985-1996
26. Xiang Z.Q., Gao G.P., Reyes-Sandoval A., Li Y., Wilson J.M., and Ertl H.C. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. Journal of Virology 77 20 (2003) 10780-10789
27. Faber M., Pulmanausahakul R., Hodawadekar S.S., Spitsin S., McGettigan J.P., Schnell M.J., et al. Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. Journal of Virology 76 7 (2002) 3374-3381
28. McGettigan J.P., Sarma S., Orenstein J.M., Pomerantz R.J., and Schnell M.J. Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. Journal of Virology 75 18 (2001) 8724-8732
29. Dietzschold B., Wunner W.H., Wiktor T.J., Lopes A.D., Lafon M., Smith C.L., et al. Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proceedings of the National Academy of Sciences of the United States of America 80 1 (1983) 70-74
30. Schnell M.J., Foley H.D., Siler C.A., McGettigan J.P., Dietzschold B., and Pomerantz R.J. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proceedings of the National Academy of Sciences of the United States of America 97 7 (2000) 3544-3549
31. Mebatsion T., Weiland F., and Conzelmann K.K. Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. Journal of Virology 73 1 (1999) 242-250
32. Schnell M.J. Viral vectors as potential HIV-1 vaccines. FEMS Microbiology Letters 200 2 (2001) 123-129
33. Morimoto K., Hooper D.C., Carbaugh H., Fu Z.F., Koprowski H., and Dietzschold B. Rabies virus quasispecies: implications for pathogenesis. Proceedings of the National Academy of Sciences of the United States of America 95 6 (1998) 3152-3156
34. McGettigan J.P., Koser M.L., McKenna P.M., Smith M.E., Marvin J.M., Eisenlohr L.C., et al. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2. Virology 344 2 (2006) 363-377
35. Tan G.S., Preuss M.A., Williams J.C., and Schnell M.J. The dynein light chain 8 binding motif of rabies virus phosphoprotein promotes efficient viral transcription. Proceedings of the National Academy of Sciences of the United States of America 104 17 (2007) 7229-7234
36. Dulina A.V., Morogova V.M., Shafeeva R.S., and Pogrebniak E.M. Antigenic activity and the reactogenicity of a concentrated, purified, UV-inactivated cultured rabies vaccine. Zhurnal Mikrobiologii, Epidemiologii, Iimmunobiologii 9 (1983) 47-50
37. Thoulouze M.I., Lafage M., Montano-Hirose J.A., and Lafon M. Rabies virus infects mouse and human lymphocytes and induces apoptosis. Journal of Virology 71 10 (1997) 7372-7380
38. WHO. Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonic eggs. WHO Technical Report Series No. 941; 2007.
39. Markine-Goriaynoff D., van der Logt J.T., Truyens C., Nguyen T.D., Heessen F.W., Bigaignon G., et al. IFN-gamma-independent IgG2a production in mice infected with viruses and parasites. International Immunology 12 2 (2000) 223-230
40. Rupprecht C.E., Hanlon C.A., Blanton J., Manangan J., Morrill P., Murphy S., et al. Oral vaccination of dogs with recombinant rabies virus vaccines. Virus Research 111 1 (2005) 101-105 [see comment]
41. Sasaki S., Amara R.R., Oran A.E., Smith J.M., and Robinson H.L. Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nature Biotechnology 19 6 (2001) 543-547
42. Sasaki S., Xin K.Q., Okudela K., Okuda K., and Ishii N. Immunomodulation by apoptosis-inducing caspases for an influenza DNA vaccine delivered by gene gun. Gene Therapy 9 12 (2002) 828-831
43. Restifo N.P. Vaccines to die for. Nature Biotechnology 19 6 (2001) 527-528 [comment]
44. Morimoto K., Hooper D.C., Spitsin S., Koprowski H., and Dietzschold B. Pathogenicity of different rabies virus variants inversely correlates with apoptosis and rabies virus glycoprotein expression in infected primary neuron cultures. Journal of Virology 73 1 (1999) 510-518
45. Pulmanausahakul R., Faber M., Morimoto K., Spitsin S., Weihe E., Hooper D.C., et al. Overexpression of cytochrome C by a recombinant rabies virus attenuates pathogenicity and enhances antiviral immunity. Journal of Virology 75 22 (2001) 10800-10807
46. Lay S., Prehaud C., Dietzschold B., and Lafon M. Glycoprotein of nonpathogenic rabies viruses is a major inducer of apoptosis in human jurkat T cells. Annals of the New York Academy of Sciences 1010 (2003) 577-581
47. Baloul L., and Lafon M. Apoptosis and rabies virus neuroinvasion. Biochimie 85 8 (2003) 777-788
48. Megret F., Prehaud C., Lafage M., Batejat C., Escriou N., Lay S., et al. Immunopotentiation of the antibody response against influenza HA with apoptotic bodies generated by rabies virus G-ERA protein-driven apoptosis. Vaccine 16 23 (2005) 5342-5350
49. Hilleman M.R. Six decades of vaccine development-a personal history. Nature Medicine 4 5 Suppl. (1998) 507-514
50. Burton D.R., and Parren P.W. Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection?. Nature Medicine 6 2 (2000) 123-125
51. Nimmerjahn F., Bruhns P., Horiuchi K., and Ravetch J.V. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23 1 (2005) 41-51 [see comment]
52. Nimmerjahn F., and Ravetch J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310 5753 (2005) 1510-1512 [see comment]
53. Woof J.M., and Burton D.R. Human antibody-Fc receptor interactions illuminated by crystal structures. Nature Reviews. Immunology 4 2 (2004) 89-99
54. Nimmerjahn F., and Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nature Reviews. Immunology 8 1 (2008) 34-47